Novo Nordisk A/S


Industry / private company

Location:
Kopenhagen (Copenhagen), Denmark


Research projects with FAU researchers


(Advanced Computed Tomography for dimensional and surface measurements in industry):
AdvanCT: Advanced Computed Tomography for dimensional and surface measurements in industry
Prof. Dr.-Ing. Tino Hausotte
(01/06/2018 - 31/05/2021)
(Multi-sensor metrology for microparts in innovative industrial products):
Microparts: Multi-sensor metrology for microparts in innovative industrial products
Prof. Dr.-Ing. Tino Hausotte
(01/09/2013 - 31/05/2016)


Publications in cooperation with FAU scientists


Nauck, M.A., Buse, J.B., Mann, J., Pocock, S., Bosch-Traberg, H., Frimer-Larsen, H.,... Gray, A. (2019). Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obesity & Metabolism, 21(3), 525-532. https://dx.doi.org/10.1111/dom.13547
Mann, J., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T.,... Poulter, N.R. (2019). Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial". Circulation, 139(22), e1017-e1018. https://dx.doi.org/10.1161/CIRCULATIONAHA.119.040419
Husain, M., Bain, S.C., Mann, J., Nauck, M., Poulter, N., Baeres, F.M.M.,... Marso, S. (2018). Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events. In EUROPEAN HEART JOURNAL (pp. 490-490). Munich, GERMANY: OXFORD: OXFORD UNIV PRESS.
Tuncel, J., Haag, S., Hoffmann, M., Yau, A.C.Y., Hultqvist, M., Olofsson, P.,... Holmdahl, R. (2016). Animal Models of Rheumatoid Arthritis (I): Pristane-Induced Arthritis in the Rat. PLoS ONE, 11(5), e0155936. https://dx.doi.org/10.1371/journal.pone.0155936
Petrie, J.R., Marso, S.P., Bain, S.C., Franek, E., Jacob, S., Masmiquel, L.,... Poulter, N.R. (2016). LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. Journal of Hypertension, 34(6), 1140-50. https://dx.doi.org/10.1097/HJH.0000000000000890
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J., Nauck, M.A.,... Buse, J.B. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311-22. https://dx.doi.org/10.1056/NEJMoa1603827
Daniels, G.H., Hegedus, L., Marso, S.P., Nauck, M.A., Zinman, B., Bergenstal, R.M.,... Tuttle, M. (2015). LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. Diabetes Obesity & Metabolism, 17(5), 477-86. https://dx.doi.org/10.1111/dom.12444

Last updated on 2015-09-12 at 12:14